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Abstract




The pyrrolomorphinan and indolomorphinan pharmacophores are a feature of a range of ligands selective for the -opioid receptor (DOPr) and the  opioid receptor (KOPr). Among these are naltrindole (1a; NTI) and norbinaltorphimine (2a; norBNI) the prototype selective ligands for DOPr and KOPr respectively. ADDIN EN.CITE ,  N-Benzylnaltrindole (BNTI; 1b) is a potent DOPr antagonist with long duration of action in vivo when administered intracerebroventricularly (i.c.v.). HYPERLINK \l "_ENREF_3" \o "Korlipara, 1994 #507"  ADDIN EN.CITE <EndNote><Cite><Author>Korlipara</Author><Year>1994</Year><RecNum>507</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>507</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">507</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Korlipara, V. L.</author><author>Takemori, A. E.</author><author>Portoghese, P. S.</author></authors></contributors><titles><title>N-BENZYLNALTRINDOLES AS LONG-ACTING DELTA-OPIOID RECEPTOR ANTAGONISTS</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>1882-1885</pages><volume>37</volume><number>12</number><dates><year>1994</year><pub-dates><date>Jun 10</date></pub-dates></dates><isbn>0022-2623</isbn><accession-num>WOS:A1994NR64700018</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:A1994NR64700018</url></related-urls></urls><electronic-resource-num>10.1021/jm00038a018</electronic-resource-num></record></Cite></EndNote>3 When administered peripherally, the related compound N-BenzylnorBNI (BnorBNI; 2b) displays early onset MOPr agonist activity in the tail withdrawal antinociception assay that is additive with the KOPr agonist activity of U69593. However when administered i.c.v. 2b selectively inhibited the antinociceptive activity of U69593. HYPERLINK \l "_ENREF_4" \o "Chauvignac, 2005 #44"  ADDIN EN.CITE <EndNote><Cite><Author>Chauvignac</Author><Year>2005</Year><RecNum>44</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">44</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Chauvignac, C.</author><author>Miller, C. N.</author><author>Srivastava, S. K.</author><author>Lewis, J. W.</author><author>Husbands, S. M.</author><author>Traynon, J. R.</author></authors></contributors><auth-address>Husbands, SM&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA</auth-address><titles><title>Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist</title><secondary-title>Journal of Medicinal Chemistry</secondary-title><alt-title>J Med Chem</alt-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><alt-periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></alt-periodical><pages>1676-1679</pages><volume>48</volume><number>5</number><keywords><keyword>nor-binaltorphimine</keyword><keyword>mediated antinociception</keyword><keyword>potent</keyword><keyword>agonists</keyword><keyword>binding</keyword><keyword>mouse</keyword></keywords><dates><year>2005</year><pub-dates><date>Mar 10</date></pub-dates></dates><isbn>0022-2623</isbn><accession-num>ISI:000227392200039</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://000227392200039</url></related-urls></urls><electronic-resource-num>Doi 10.1021/Jm049172n</electronic-resource-num><language>English</language></record></Cite></EndNote>4
Pursuing our interest in N-benzylpyrrolomorphinan structures we investigated reaction of the benzylimines and methylimines of oxymorphone and naltrexone with Michael acceptors. The reactions of -nitrostyrenes with the imines generated in-situ produced 4’-aryl-1-benzylpyrrolomorphinan ligands (3). ADDIN EN.CITE 5 These ligands had modest selectivity in receptor binding assays for DOPr over KOPr but not over MOPr. In the [35S]GTPS assays they showed predominantly opioid receptor antagonist activity with substantial DOPr selectivity particularly over KOPr. The lead compound (3a) in vivo had slow onset as an antagonist of the selective DOPr agonist SNC80 with potency comparable to that of NTI. ADDIN EN.CITE 5




The synthetic procedure for accessing the new compounds is shown in Scheme 1. Briefly, the appropriate oxymorphone was treated with an amine in refluxing ethanol under anhydrous conditions in the presence of p-toluene sulfonic acid. The resulting imine was reacted with ethyl acrylate to give the desired morphinans in 20 – 40% yield after purification.

2.2	Biological Evaluation
The test ligands were evaluated in binding assays in membranes prepared from human recombinant opioid receptors transfected into chinese hamster ovary (CHO) cells in which the displaced radioligands were [3H]DAMGO (MOPr), [3H]Cl-DPDPE (DOPr), [3H]U69593 (KOPr) and [3H]nociceptin (Table 1). Details of these assays have been described previously. ADDIN EN.CITE 9 

The pyridomorphinans (5) generally had significantly higher affinity for opioid receptors than did the pyrrolomorphinans (4) when comparing ligands with the same 17(N)-substituent. In the 17-methyl series (5a-f) MOPr affinity was high (0.29 – 12.7 nM), similar to DOPr affinity (0.92 – 9.39 nM) and significantly higher than KOPr affinity (1.98 – 182 nM). Benzyl substitution on the pyridinonyl (1’-) nitrogen (5b, 5e, 5f) generally produced higher affinity for all receptor types than did equivalent methyl substitution (5a, 5c, 5d). Substitution in the 5’-position of the pyridinone ring with the hydroxyethyl group reduced MOPr and KOPr affinity with only minor effects on DOPr affinity, with the 5’-substituted ligands (5c, 5e) having somewhat higher affinity than equivalent 5’-substituted ligands (5d, 5f). The affinity of the 17-cyclopropylmethyl series (5g-5k, 5n) for all opioid receptors was low nanomolar to subnanomolar with no significant selectivity. The binding affinities for all the pyridinones (5) followed a general SAR pattern in which 5’-substitution in the pyridinonyl ring reduced affinity for all three opioid receptors with the least effect shown at DOPr.

The in vitro functional response of the previously synthesised ligands HYPERLINK \l "_ENREF_6" \o "Shefali, 2002 #71"  ADDIN EN.CITE <EndNote><Cite><Author>Shefali</Author><Year>2002</Year><RecNum>71</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Shefali</author><author>Srivastava, S. K.</author><author>Hall, L. D.</author><author>Lewis, J. W.</author><author>Husbands, S. M.</author></authors></contributors><auth-address>Husbands, SM&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England</auth-address><titles><title>Michael reactions of benzylimines derived from morphinan-6-ones: Synthesis of pyrrolo- and pyridinomorphinans</title><secondary-title>Helvetica Chimica Acta</secondary-title><alt-title>Helv Chim Acta</alt-title></titles><periodical><full-title>Helvetica Chimica Acta</full-title><abbr-1>Helv. Chim. Acta</abbr-1><abbr-2>Helv Chim Acta</abbr-2></periodical><alt-periodical><full-title>Helvetica Chimica Acta</full-title><abbr-1>Helv. Chim. Acta</abbr-1><abbr-2>Helv Chim Acta</abbr-2></alt-periodical><pages>1790-1799</pages><volume>85</volume><number>6</number><keywords><keyword>opioid receptor antagonists</keyword><keyword>imines</keyword><keyword>derivatives</keyword></keywords><dates><year>2002</year></dates><isbn>0018-019X</isbn><accession-num>ISI:000176722300020</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://000176722300020</url></related-urls></urls><language>English</language></record></Cite></EndNote>6 was determined in [35S]GTPS assays using membranes from cloned human receptors transfected into CHO cells ADDIN EN.CITE 9 where the reference ligands for efficacy comparison and/or determination of antagonism potency (Ke/nM) were DAMGO (MOPr), DPDPE (DOPr) and U69593 (KOPr). In order to expedite the evaluation process a primary screen for the newly synthesized ligands (5k-5p) was put in place with efficacy determination as before, but testing at a single high dose (10M) to determine maximal efficacy for MOPr, KOPr and the nociceptin/orphanin FQ peptide receptor (NOPr) (Table 3). Efficacy at NOPr was screened for due to our interest in the possibility of developing MOPr/KOPr antagonists with NOPr partial agonist activity as potential relapse prevention agents for the treatment of drug addiction.,   A limited selection of compounds from the screen (5k, 5n) were then evaluated more fully (Tables 1 and 2).
The in vitro opioid receptor profiles of the pyrolomorphinans (4) were markedly influenced by the nature of the 17(N)-substituent. The 17-methyl derivative (4a) was a low potency partial agonist, but with a maximal response approaching that seen with the standard full agonists at MOPr (86% stimulation) and DOPr (74% stimulation) and a very low potency and very low efficacy KOPr partial agonist (23% stimulation). In contrast the 17-CPM analogue (4b) showed no evidence of agonism, but was an antagonist with nM affinity for all three opioid receptors.
All of the original pyridinones (5a-5j) were KOP receptor antagonists with marked difference of potency between the 17-methyl (5a – 5f) and 17-CPM (5g – 5k) groups (Table 2). Thus 5k was over 160-fold more potent as an antagonist (Ke 0.13nM) than 5b (Ke 21nM) and 5i was 40-fold more potent (Ke 0.73nM) than 5e (Ke 29nM). Whereas all the 17-CPM pyridinones (5g – 5k) were potent antagonists at all three opioid receptors, the 17-methyl series (5a – 5f) were partial agonists at MOPr of moderate efficacy and potency with the exception of the 5’-hydroxyethyl derivative 5e which had low MOPr efficacy (17% of DAMGO) and so acted as a MOPr antagonist (Ke 33nM), though of  two orders of magnitude lower potency than the equivalent 17-CPM ligand (5i; Ke 0.35nM). The 17-methyl pyridinones (5a – 5f) were also DOPr partial agonists generally of higher efficacy (66 - 94% of DPDPE) and potency than as MOPr partial agonists (17 – 52% of DAMGO).
As there was no evidence that having a 5’-substituent was beneficial to activity at opioid receptors, the new group of 17-CPM pyridomorphinans were unsubstituted in the 5’-position in the pyridinone ring (5k, 5l, 5n, 5o, 5p) and the 17-allyl analogue 5m. These new ligands showed no evidence of agonist efficacy for MOPr and KOPr at a 10M concentration and even showed signs of inverse agonist activity at KOPr (Table 3). They also showed very low levels of efficacy for NOPr. Variation of the 1’-N substituent on the pyridinone ring, the 17(N)-substituent or substitution in the phenyl ring of the 1’-benzyl group had very little effect on the screened profile of the new ligands (Table 3).

3.	Discussion
The known pyrrolomorphinan 6a is a non-selective opioid antagonist HYPERLINK \l "_ENREF_12" \o "Portoghese, 1988 #509"  ADDIN EN.CITE <EndNote><Cite><Author>Portoghese</Author><Year>1988</Year><RecNum>509</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>509</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">509</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Portoghese, P. S.</author><author>Nagase, H.</author><author>Lipkowski, A. W.</author><author>Larson, D. L.</author><author>Takemori, A. E.</author></authors></contributors><titles><title>BINALTORPHIMINE-RELATED BIVALENT LIGANDS AND THEIR KAPPA-OPIOID RECEPTOR ANTAGONIST SELECTIVITY</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>836-841</pages><volume>31</volume><number>4</number><dates><year>1988</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0022-2623</isbn><accession-num>WOS:A1988M716200026</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:A1988M716200026</url></related-urls></urls><electronic-resource-num>10.1021/jm00399a026</electronic-resource-num></record></Cite></EndNote>12 whereas the equivalent indolomorphinan NTI (1a) is a highly selective DOPr antagonist. HYPERLINK \l "_ENREF_2" \o "Portoghese, 1990 #505"  ADDIN EN.CITE <EndNote><Cite><Author>Portoghese</Author><Year>1990</Year><RecNum>505</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>505</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Portoghese, P. S.</author><author>Sultana, M.</author><author>Takemori, A. E.</author></authors></contributors><titles><title>DESIGN OF PEPTIDOMIMETIC DELTA-OPIOID RECEPTOR ANTAGONISTS USING THE MESSAGE ADDRESS CONCEPT</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>1714-1720</pages><volume>33</volume><number>6</number><dates><year>1990</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>0022-2623</isbn><accession-num>WOS:A1990DF28900028</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:A1990DF28900028</url></related-urls></urls><electronic-resource-num>10.1021/jm00168a028</electronic-resource-num></record></Cite></EndNote>2 The difference is due to substantially lower DOPr potency and higher MOPr and KOPr antagonist potency of 6a. DOPr antagonist potency and selectivity was restored in 6a by pyrrole-ring substitution in the 4’ and 5’-positions as in 6b, HYPERLINK \l "_ENREF_13" \o "FarouzGrant, 1997 #510"  ADDIN EN.CITE <EndNote><Cite><Author>FarouzGrant</Author><Year>1997</Year><RecNum>510</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>510</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">510</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>FarouzGrant, F.</author><author>Portoghese, P. S.</author></authors></contributors><titles><title>Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>1977-1981</pages><volume>40</volume><number>13</number><dates><year>1997</year><pub-dates><date>Jun 20</date></pub-dates></dates><isbn>0022-2623</isbn><accession-num>WOS:A1997XG18700005</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:A1997XG18700005</url></related-urls></urls><electronic-resource-num>10.1021/jm970189y</electronic-resource-num></record></Cite></EndNote>13 with further enhancement of DOPr potency by introduction of a 1’(N)-benzyl substituent as in 3a. ADDIN EN.CITE 5 The herein reported example (4b) is a non-selective opioid antagonist which is best compared with 6b since a side chain CO2Et is regarded as an isostere of a phenyl group HYPERLINK \l "_ENREF_14" \o "Feldman, 1991 #511"  ADDIN EN.CITE <EndNote><Cite><Author>Feldman</Author><Year>1991</Year><RecNum>511</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>511</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">511</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Feldman, P. L.</author><author>James, M. K.</author><author>Brackeen, M. F.</author><author>Bilotta, J. M.</author><author>Schuster, S. V.</author><author>Lahey, A. P.</author><author>Lutz, M. W.</author><author>Johnson, M. R.</author><author>Leighton, H. J.</author></authors></contributors><titles><title>DESIGN, SYNTHESIS, AND PHARMACOLOGICAL EVALUATION OF ULTRASHORT-ACTING TO LONG-ACTING OPIOID ANALGESICS</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>2202-2208</pages><volume>34</volume><number>7</number><dates><year>1991</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0022-2623</isbn><accession-num>WOS:A1991FW17000041</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:A1991FW17000041</url></related-urls></urls><electronic-resource-num>10.1021/jm00111a041</electronic-resource-num></record></Cite></EndNote>14 so that the 4’-benzyl group of 6b is comparable to the 4’-CH2CO2Et group of 4b. Despite the structural differences between 6b and 4b in the 1’-(N) and 5’-positions (substituents R1 and R3 in structure 6) they have comparable DOPr antagonist potency (Ke 6b 2.1nM, 4b 6.8nM) but equally high MOPr (6.6 nM) and KOPr (4.3 nM) antagonist potencies of 4b means DOPr antagonist selectivity in 4b is lost whereas 6b was 50-fold selective over both MOPr and KOPr.13 Since it was established that the 1’-(N)-benzyl group had a positive effect particularly on DOPr antagonist potency, ADDIN EN.CITE 5 it appears that the 5’-hydroxyl group has the opposite effect.  
It is of interest to compare the pyridinones reported herein (5) with the pyridomorphinans (7) reported by the Ananthan group. ADDIN EN.CITE 8 Most of the attention in ligands of structure 7 was directed at ligands with 5’-aryl or heteroaryl substituents giving the lead compound SoRI9409 (7c), HYPERLINK \l "_ENREF_15" \o "Rothman, 2009 #513"  ADDIN EN.CITE <EndNote><Cite><Author>Rothman</Author><Year>2009</Year><RecNum>513</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>513</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">513</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>Rothman, Richard B.</author><author>Ananthan, Subramaniam</author><author>Bilsky, Edward J.</author></authors><secondary-authors><author>Dean, R. L.</author><author>Bilsky, E. J.</author><author>Negus, S. S.</author></secondary-authors></contributors><titles><title>Novel Opioid Antagonists with Mixed/Dual Selectivity</title><secondary-title>Opiate Receptors and Antagonists: From Bench to Clinic</secondary-title></titles><pages>137-151</pages><dates><year>2009</year></dates><isbn>978-1-58829-881-2(H)</isbn><accession-num>BCI:BCI200900400311</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://BCI:BCI200900400311</url></related-urls></urls><electronic-resource-num>10.1007/978-1-59745-197-0_8</electronic-resource-num></record></Cite></EndNote>15 a MOPr agonist and DOPr antagonist showing antinociception with minimal tolerance in multiple dosing regimes. In contrast, substituents in the 5’-position in the pyridinones (5) are alkyl, particularly methyl and hydroxyethyl. Thus comparison will be made between ligands from the two series with no 5’-substituent.This means comparing 5b with 7a and 5k with 7b. 5b has highest binding affinity ot MOPr (Ki 0.29 nM) with around 3-fold lower affinity at DOPr and 6-fold lower at KOPr; 7a also has highest affinity at MOPr but that is 27-fold lower than the MOPr affinity of 5b.  DOPr and KOPr affinity of 7a is also very much lower than that of 5b, 20-fold and 130-fold respectivly. HYPERLINK \l "_ENREF_16" \o "Ananthan, 2004 #514"  ADDIN EN.CITE <EndNote><Cite><Author>Ananthan</Author><Year>2004</Year><RecNum>514</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>514</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">514</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ananthan, Subramaniam</author><author>Khare, Naveen K.</author><author>Saini, Surendra K.</author><author>Seitz, Lainne E.</author><author>Bartlett, Jeffrey L.</author><author>Davis, Peg</author><author>Dersch, Christina M.</author><author>Porreca, Frank</author><author>Rothman, Richard B.</author><author>Bilsky, Edward J.</author></authors></contributors><titles><title>Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>1400-1412</pages><volume>47</volume><number>6</number><dates><year>2004</year><pub-dates><date>2004/03/01</date></pub-dates></dates><publisher>American Chemical Society</publisher><isbn>0022-2623</isbn><urls><related-urls><url>http://dx.doi.org/10.1021/jm030311v</url></related-urls></urls><electronic-resource-num>10.1021/jm030311v</electronic-resource-num><access-date>2014/01/15</access-date></record></Cite></EndNote>16 The effect of replacing the 17-methyl group of 5b with the CPM group (5k) is relatively small since both ligands have high affinity for all three opioid receptors. Similar enhancement of binding affinity is seen in 7b in comparison with 7a; in both series improvement in KOPr affinity is most pronounced.
The in vitro profile in [35S]GTPS assays of the 17-(N)-methyl pyridinone 5b is KOPr antagonist, MOPr partial agonist and DOPr full agonist giving a clear rank order of efficacy DOPr>MOPr>KOPr. The pyridomorphinan 7a was reported as having no DOPr or KOPr agonist activity (though no antagonist activity could be detected) and extremely low potency MOPr partial agonist activity in a [35S]GTPS assay (EC50 3000nM).16 In isolated tissue assays the MOPr agonist activity of 7a was reported as being confirmed (IC50 523 nM) in the guinea pig ileum (GPI: a tissue that is sensitive to agonists acting at MOPr and KOPr) but in mouse vas deferens (MVD: a tissue particularly sensitive to DOPr agonists, but also to MOPr and KOPr agonists) a DOPr partial agonist response was recorded (49% of maximum). HYPERLINK \l "_ENREF_16" \o "Ananthan, 2004 #514"  ADDIN EN.CITE <EndNote><Cite><Author>Ananthan</Author><Year>2004</Year><RecNum>514</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>514</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">514</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ananthan, Subramaniam</author><author>Khare, Naveen K.</author><author>Saini, Surendra K.</author><author>Seitz, Lainne E.</author><author>Bartlett, Jeffrey L.</author><author>Davis, Peg</author><author>Dersch, Christina M.</author><author>Porreca, Frank</author><author>Rothman, Richard B.</author><author>Bilsky, Edward J.</author></authors></contributors><titles><title>Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone</title><secondary-title>Journal of Medicinal Chemistry</secondary-title></titles><periodical><full-title>Journal of Medicinal Chemistry</full-title><abbr-1>J. Med. Chem.</abbr-1><abbr-2>J Med Chem</abbr-2></periodical><pages>1400-1412</pages><volume>47</volume><number>6</number><dates><year>2004</year><pub-dates><date>2004/03/01</date></pub-dates></dates><publisher>American Chemical Society</publisher><isbn>0022-2623</isbn><urls><related-urls><url>http://dx.doi.org/10.1021/jm030311v</url></related-urls></urls><electronic-resource-num>10.1021/jm030311v</electronic-resource-num><access-date>2014/01/15</access-date></record></Cite></EndNote>16 Thus the rank order of efficacies for opioid receptors of 7a appears to be MOPr>DOPr>KOPr with the major difference from 5b being the very low potency for all opioid receptor activity and particularly at DOPr where the efficacy difference was also very pronounced.
As shown in tables 1 and 2, the 17(N)-CPM pyridinone (5k) is an extremely potent non-selective opioid receptor antagonist. The equivalent pyridomorphinan (7b) in the GPI assay showed MOPr antagonist activity with Ke = 164  nM ADDIN EN.CITE 8 representing 800-fold lower potency than that of 5k in the [35S]GTPS assay.

The effect of substitution in the 5’-position of the pyridinones (5) and pyridomorphinans (7) is interesting though the nature of the substituents in the two series is different. In the 17(N)-Me group of pyridinones (5a-5f) 5’-substitution of methyl and hydroxyethyl groups has a substantial negative influence on affinity for all three opioid receptors and in [35S]GTPS assays results in much lower potencies without changing the rank order of efficacy DOPr>MOPr>KOPr. Aryl substitution in the 5’-position of 7a and 7b has a major effect on opioid receptor binding profile by substantially increasing DOPr affinity and reducing MOPr affinity resulting in DOPr selectivity.16 In vitro the 5’-aryl analogues of 7a are not dissimilar to the parent.

4.	Conclusions





Reagents and solvents were purchased from Sigma-Aldrich or Alfa Aesar and used as received. 1H and 13C NMR spectra were obtained with a Brucker-400-MHz instrument (1H at 400 MHz, 13C at 100 MHz); δ in ppm, J in Hz with TMS as an internal standard. ESIMS: microTOF (BRUKER). Microanalysis: Perkin-Elmer 240C analyzer. Column Chromatography was performed using pre-packed column in combi flash instrument. Ligands were tested as their hydrochloride salts, prepared by adding 5 equivalent of HCl (1N solution in diethyl ether) in a solution of compound in anhydrous methanol. Synthetic methods are detailed for one example in each series. Full details for all experiments can be found in the supporting information. All reactions were carried out under an inert atmosphere of nitrogen unless otherwise indicated. The procedure and analysis for the new compounds, 5k – 5p is given below, 5a – 5j have been reported previously. HYPERLINK \l "_ENREF_6" \o "Shefali, 2002 #71"  ADDIN EN.CITE <EndNote><Cite><Author>Shefali</Author><Year>2002</Year><RecNum>71</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="d0ete9wrav5fe7e2z04v2t0yrrswvr0farzs">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Shefali</author><author>Srivastava, S. K.</author><author>Hall, L. D.</author><author>Lewis, J. W.</author><author>Husbands, S. M.</author></authors></contributors><auth-address>Husbands, SM&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon, England&#xD;Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England</auth-address><titles><title>Michael reactions of benzylimines derived from morphinan-6-ones: Synthesis of pyrrolo- and pyridinomorphinans</title><secondary-title>Helvetica Chimica Acta</secondary-title><alt-title>Helv Chim Acta</alt-title></titles><periodical><full-title>Helvetica Chimica Acta</full-title><abbr-1>Helv. Chim. Acta</abbr-1><abbr-2>Helv Chim Acta</abbr-2></periodical><alt-periodical><full-title>Helvetica Chimica Acta</full-title><abbr-1>Helv. Chim. Acta</abbr-1><abbr-2>Helv Chim Acta</abbr-2></alt-periodical><pages>1790-1799</pages><volume>85</volume><number>6</number><keywords><keyword>opioid receptor antagonists</keyword><keyword>imines</keyword><keyword>derivatives</keyword></keywords><dates><year>2002</year></dates><isbn>0018-019X</isbn><accession-num>ISI:000176722300020</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://000176722300020</url></related-urls></urls><language>English</language></record></Cite></EndNote>6

5.2	Synthesis
5.2.1	General Procedure. Naltrexone (0.80g, 2.35 mmol) was dissolved in 2 ml of anhydrous ethanol under a nitrogen atmosphere. Catalytic p-toluene sulfonic acid (10 mg) and activated molecular sieves (50mg) were added. The reaction mixture was stirred for 10 min and the appropriate amine (RNH2; 2.35 mmol) was added. The reaction mixture was refluxed for 5 hr before adding ethyl acrylate (0.26ml, 2.35 mmol) and again refluxing for 18 hr. After completion, the reaction mixture was cooled to room temperature, filtered and washed with dichloromethane (50 ml) and the organic layer was washed with water (2x20 ml) and brine (20 ml). The organic layer was dried over magnesium sulphate, concentrated under reduced pressure to obtain crude product which was purified by flash chromatography using methanol:dichloromethane:ammonium hydroxide (1:98.5:0.5).  Yield (20-40 %)    

5.2.2.	1’-Benzyl-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-4’,5’-dihydro-3,14-dihydroxy-pyrido[2,3: 6,7-]morphinan-6(1H)-one (5k)
White Solid; 1H NMR (CDCl3)  0.10 -0.13 (2H, m), 0.51-0.54 (2H, m), 0.80-0.83 (1H, m), 1.54 (2H, d, J=13.00 Hz), 2.10-2.26 (4H, m), 2.34-2.46 (4H, m), 2.56-2.63 (3H, m), 3.01 (1H, d, J=18.48 Hz), 3.12 (1H, d, J=6.44Hz), 4.93 (1H, d, J=16.72Hz), 5.04 (1H, s), 5.33 (1H, d, J=16.72Hz), 6.52 (1H, d, J=8.16 Hz), 6.61 (1H, d, J=8.16 Hz), 7.19-7.25 (2H, m), 7.31-7.53 (3H, m); 13C NMR, (CDCl3) δ 3.60, 3.96, 9.29, 22.82, 26.22, 30.85, 31.28, 36.92, 43.44, 44.37, 46.68, 59.31, 61.20, 70.09, 86.52, 116.80, 118.71, 118.97,  124.92, 125.82, 126.75, 128.55, 128.76, 131.02, 138.75, 138.94, 142.38, 170.41. HRMS, m/z for (C30H32N2O4Na) [MNa]+, calcd-507.2260, found-507.2242. Anal. (C30H32N2O4 ·HCl·2.5H2O) C, H, N.

5.2.3.	1’-Phenylethyl-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-4’,5’-dihydro-3,14-dihydroxy-pyrido[2,3: 6,7-]morphinan-6(1H)-one (5l)








White Solid; 1H NMR (CDCl3)  0.11-0.15 (2H, m), 0.52-0.56 (2H, m), 0.83-0.85 (1H, m), 1.01-1.05 (2H, m), 1.17-1.25 (3H, m), 1.45-1.52 (1H, m), 1.65-1.78 (7H, m), 2.03-2.36 (5H, m), 2.38-2.43 (4H, m), 2.54-2.65 (2H, m),  3.04 (1H, d, J=18.52 Hz), 3.13 (1H, d, J=6.36 Hz), 3.20 (1H, dd, J=5.84 and 14.32 Hz), 4.17 (1H, dd, J=8.76 and 14.32 Hz), 5.08 (1H, s), 6.53 (1H, d, J=8.16 Hz), 6.66 (1H, d, J=8.16 Hz); 13C NMR, (CDCl3) δ 3.71, 3.89, 9.35, 22.90, 25.50, 25.74, 26.00, 26.39, 30.40, 30.83, 30.94, 31.64,  36.61, 37.80, 43.50, 46.21, 46.52, 59.40, 61.38, 69.67, 85.39, 117.10, 118.81, 119.51, 124.59, 128.91, 131.15, 139.43, 142.67, 170.78. HRMS, m/z for (C30H38N2O4Na) [MNa]+, calcd-513.2729, found-513.2741. Anal. (C30H38N2O4 ·HCl·H2O ·0.7CH2Cl2) C, H, N.

5.2.6.	1’-(m-Chlorobenzyl)-17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-4’,5’-dihydro-3,14-dihydroxy-pyrido[2,3: 6,7-]morphinan-6(1H)-one (5o)
White Solid; 1H NMR (CDCl3)  0.11-0.13 (2H, m), 0.51-0.54 (2H, m), 0.80-0.83 (1H, m), 1.54 (2H, d, J=12.92 Hz), 2.05-2.26 (4H, m), 2.34-2.41 (4H, m), 2.56-2.65 (3H, m), 3.02 (1H, d, J=18.48 Hz), 3.14 (1H, d, J=6.44Hz), 4.81 (1H, d, J=16.76Hz), 4.96 (1H, s), 5.38 (1H, d, J=16.76 Hz), 6.53 (1H, d, J=8.16 Hz), 6.64 (1H, d, J=8.16 Hz), 7.08 (1H, d, J=7.12 Hz), 7.21 (3H, m); 13C NMR, (CDCl3) δ 3.61, 3.97, 9.29, 22.82, 26.06, 30.69, 31.37, 36.82, 43.43, 43.88, 46.67, 59.32, 61.16, 70.03, 86.21, 116.94, 119.06, 119.08, 124.08, 124.86, 126.35, 127.07, 128.55, 129.83, 130.97, 134.52, 139.08, 140.74, 142.38, 170.52. HRMS, m/z for (C30H32ClN2O4) [MH]+, calcd-519.2051, found-519.2052. Anal. (C30H31ClN2O4 ·HCl·H2O·0.4CH2Cl2) C, H, N.

5.2.7.	1’-(m-Fluorobenzyl)-17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-4’,5’-dihydro-3,14-dihydroxy-pyrido[2,3: 6,7-]morphinan-6(1H)-one (5p)




All receptors were in CHO cells transfected with human receptor cDNA. The cells were grown in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum, in the presence of 0.4 mg ml−1 G418 and 0.1% penicillin/streptomycin, in 100-mm plastic culture dishes. For binding assays, the cells were scraped off the plate at confluence.

5.3.2	 Receptor binding
Binding to cell membranes was conducted in a 96-well format. Cells were removed from the plates by scraping with a rubber policeman, homogenized in 50 mM Tris pH 7.5, using a Polytron homogenizer, then centrifuged once and washed by an additional centrifugation at 27 000 g for 15 min. The pellet was resuspended in Tris, and the suspension incubated with [3H]DAMGO ([d-Ala2, N-Me-Phe4,Gly5-ol]enkephalin) (51 Ci mmol−1, 1.6 nM), [3H]Cl-DPDPE ([d-Pen2, d-Pen5]enkephalin) (42 Ci mmol−1, 1.4 nM), [3H]U69593 (41.7 Ci mmol−1, 1.9 nM) or [3H]nociceptin (120 Ci mmol−1, 0.2 nM) for binding to, MOP, DOP, KOP and NOP receptors, respectively. Nonspecific binding was determined with 1 μM of unlabelled DAMGO, DPDPE, ethylketocyclazocine and N/OFQ, respectively. Total volume of incubation was 1.0 ml and samples were incubated for 60 min at 25 °C. The amount of protein in the binding assay was 15 μg. The reaction was terminated by filtration using a Tomtec 96 harvester (Orange, CT, USA) through glass fibre filters. Bound radioactivity was counted on a Pharmacia Biotech beta-plate liquid scintillation counter (Piscataway, NJ, USA) and expressed in counts per minute. IC50 values were determined using at least six concentrations of each compound and calculated using Graphpad/Prism (ISI, San Diego, CA, USA). 

5.3.3		[35S]GTPγS binding
[35S]GTPγS binding was conducted basically as described by Traynor and Nahorski. Cells were scraped from tissue culture dishes into 20 mM HEPES, 1 mM EDTA, then centrifuged at 500 g for 10 min. Cells were resuspended in this buffer and homogenized using a Polytron Homogenizer. The homogenate was centrifuged at 27 000 g for 15 min, and the pellet resuspended in buffer A containing 20 mM HEPES, 10 mM MgCl2, 100 mM NaCl, pH 7.4. The suspension was recentrifuged at 27 000 g and suspended once more in buffer A. For the binding assay, membranes (8–15 μg protein) were incubated with [35S]GTPγS (50 pM), GDP (10 μM) and the appropriate compound, in a total volume of 1.0 ml, for 60 min at 25 °C. Samples were filtered over glass fibre filters and counted as described for the binding assays. Statistical analysis was conducted using the program Prism.
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Table 1: Binding (Ki/nM) affinities to opioid receptors (and for selected compounds, to NOP receptorsa)

	R	R1	R2	R3	MOPr	Ki (nM) ± SEMbKOPr	DOPr
5a5b5c5d5e5f5g5h5i5j5ka5na4a4bNaltrexoneNaltrindolenorBNI	MeMeMeMeMeMeCPMCPMCPMCPMCPMCPMMeCPM- --	MeBnMeMeBnBnBnBnBnBnBncHexMeBnBn--	HH(CH2)2OHH(CH2)2OHHMeH(CH2)2OHHHH-----	HHH(CH2)2OHH(CH2)2OHHMeH(CH2)2OHHHCH2CO2EtCH2CO2Et---	1.23±0.020.29±0.042.37±0.2812.8±3.02.03±0.473.00±0.690.56±0.030.42±0.030.43±0.101.54±0.350.18±0.050.11±0.0213.2±0.328.65±0.030.20±0.06.30±2.321.0±5.0	20.4±1.31.98±0.1948.7±1.3182±634.68±0.0215.6±2.020.95±0.130.71±0.011.29±0.182.76±0.910.15±0.030.33±0.05159±224.79±1.200.40±0.110.1±0.650.20±0.05	9.39±2.10.92±0.133.59±0.979.25±2.61.02±0.062.85±0.800.85±0.051.58±0.080.70±0.032.38±0.450.36±0.010.28±0.0582.1±9.110.0±1.310.8±3.00.20±0.055.07±0.9
a5k, NOP Ki 1300±800 nM; 5l, NOP Ki 1500±90 nM; 5n, NOP Ki 880±140 nM




Table 2: Functional activity; agonist stimulation of, and antagonist inhibition of, [35S]GTPS binding in cloned human opioid receptors 

	R	R1	R2	R3	EC50 (nM)   %stimaor (Ke/nM)MOPr	EC50 (nM)   %stimaor (Ke/nM)KOPr	EC50 (nM)   %stimaor (Ke/nM)DOPr
5a5b5c5d5ed5f5g5h5i5j5k5n4a4bNTXbNTIcnorBNI	MeMeMeMeMeMeCPMCPMCPMCPMCPMCPMMeCPM---	MeBnMeMeBnBnBnBnBnBnBncHexMeBnBn---	HH(CH2)2OHH(CH2)2OHHMeH(CH2)2OHHHH---	HHH(CH2)2OHH(CH2)2OHHMeH(CH2)2OHHHCH2CO2EtCH2CO2Et---	80.0±12    404.97±0.03       52163±31     36709±235      37(32.9±1.21)94.9±24   36(0.50±0.06)(0.60±0.04)(0.35±0.02)(1.62±0.19)(0.20±0.04)(0.27±0.07)70.5±5.6    86(6.61±0.71)(0.59±0.04)(4.26±0.33)(18.9±1.80)	(392±66) (21.3±2.8)(321±31)(2140±128)(29.3±5.9)(16.8±3.0)(0.23±0.02)(2.03±0.16)(0.73±0.17)(2.22±0.06)(0.13±0.08)(0.48±0.11)434±114     23(4.30±0.34)(1.86±0.16)(4.95±0.32)(0.039±0.004)	25.5±0.76    673.00±0.93     9411.8±0.77    6630.6±1.4    802.37±0.45     7310.6±3.6     68(0.23±0.02)(0.57±0.06)(0.47±0.01)(0.93±0.14)NDND42.5±33      74(6.79±0.81)5.44±0.75(0.11±0.005)(4.42±0.38)






Table 3: Maximal stimulation of [35S]GTPS
 binding of analogues 5k – 5o to MOP, KOP
 and NOP receptors

	Maximum  % stim’a
	MOPr	KOPr	NOPr
5k	-1 ± 4	-20 ± 9	12 ± 3
5l	1 ± 6	-10 ± 4	5 ± 7
5m	-2 ± 2	-15 ± 7	4 ± 5
5n	-1 ± 1	-5 ± 8	5 ± 3
5p	-1 ± 1	-9 ± 8	7 ± 4
5o	-1 ± 1	-11 ± 10	7 ± 4
 aAt 10 M compared to the standard agonists 


































Scheme 1: i) R’NH2, PTSA, mol. sieves, EtOH, reflux







